Struggling to control high BP? Learn about resistant hypertension, its causes, and expert-approved ways to manage it. Get ...

AstraZeneca announced that baxdrostat, a selective aldosterone synthase inhibitor, met its primary and all secondary ...

Topline data were announced from a phase 3 trial that evaluated baxdrostat in patients with uncontrolled or treatment resistant hypertension.

In addition to taking medication, paying attention to these habits can help maintain healthy blood pressure levels..resistant ...

Resistant hypertension, especially for prolonged periods, is accompanied by a substantial increase in the overall risk of cardiovascular and renal events, owing to the common coexistence of other ...

Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med 2008; 168 : 1159–1164.

In a new clinical practice guideline, the Endocrine Society advises universal screening of those with hypertension by ...

DeepQure announced today that South Korea's Ministry of Food and Drug Safety (MFDS) has approved a clinical trial of HyperQure™ RDM System, the company's novel laparoscopic renal denervation (RDN) ...

The BaxHTN study met its primary endpoint, and researchers will present more data at the ESC Congress later this summer.

Baxdrostat meets primary and all secondary endpoints in BaxHTN phase III trial in patients with uncontrolled or treatment resistant hypertension: Cambridge, UK Wednesday, July 16, ...

AstraZeneca (AZN) on Monday said that its investigational drug Baxdrostat reduced systolic blood pressure (SBP) compared with ...

Dubai: A promising new blood pressure medication could soon help thousands of UAE residents struggling with ...